MedTrace Logo

Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

NCT05182164 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2025-10-07

No results posted yet for this study

Summary

Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.

Conditions

Interventions

DRUG

Association of pembrolizumab + cabozantinib

A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg). Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis.

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • MSD France

    collaborator INDUSTRY

  • Institut Bergonié

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-25
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05182164 on ClinicalTrials.gov